Evidence map›Paper›PMID 39772241›Full record

ArticleViruses2024

MARCH8 Restricts RSV Replication by Promoting Cellular Apoptosis Through Ubiquitin-Mediated Proteolysis of Viral SH Protein.

Takashi Okura, Tatsuki Takahashi, Taichi Kameya, Fuminori Mizukoshi, Yusuke Nakai, Masatoshi Kakizaki, Mayuko Nishi, Noriyuki Otsuki, Hirokazu Kimura, Kei Miyakawa and 3 more

Abstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Programmed cell death in human respiratory syncytial virus infection.Frontiers in cellular and infection microbiology · 2025
    Pooled it
  2. Article
  3. MARCH E3 Ligases: Understudied Regulators of Pulmonary Immune Function.Journal of respiratory biology and translational medicine · 2026
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Takashi OkuraDepartment of Virology 3, National Institute of Infectious Diseases, Musashimurayama 208-0011, Tokyo, Japan.
Tatsuki TakahashiDepartment of Infectious Diseases and Host Defense, Graduate School of Medicine, Gunma University, Maebashi 371-8511, Gunma, Japan.
Taichi KameyaDepartment of Virology 3, National Institute of Infectious Diseases, Musashimurayama 208-0011, Tokyo, Japan.
Fuminori MizukoshiDepartment of Virology 3, National Institute of Infectious Diseases, Musashimurayama 208-0011, Tokyo, Japan.
Yusuke NakaiDepartment of Virology 3, National Institute of Infectious Diseases, Musashimurayama 208-0011, Tokyo, Japan.
Masatoshi KakizakiDepartment of Virology 3, National Institute of Infectious Diseases, Musashimurayama 208-0011, Tokyo, Japan.
Mayuko NishiDepartment of Virology 3, National Institute of Infectious Diseases, Musashimurayama 208-0011, Tokyo, Japan.
Noriyuki OtsukiDepartment of Virology 3, National Institute of Infectious Diseases, Musashimurayama 208-0011, Tokyo, Japan.
Hirokazu KimuraDepartment of Health Science, Graduate School of Health Sciences, Gunma Paz University, Takasaki 370-0006, Gunma, Japan.
Kei MiyakawaResearch Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Musashimurayama 208-0011, Tokyo, Japan.
Kazuya ShiratoDepartment of Virology 3, National Institute of Infectious Diseases, Musashimurayama 208-0011, Tokyo, Japan.ORCID 0000-0002-3375-9799
Wataru KamitaniDepartment of Infectious Diseases and Host Defense, Graduate School of Medicine, Gunma University, Maebashi 371-8511, Gunma, Japan.
Akihide RyoDepartment of Virology 3, National Institute of Infectious Diseases, Musashimurayama 208-0011, Tokyo, Japan.

Funding

Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research KAKENHI 22K08616 to T.O. and 23K27641 to A.R.
6 · The paper itself

Abstract

Numerous host factors function as intrinsic antiviral effectors to attenuate viral replication. MARCH8 is an E3 ubiquitin ligase that has been identified as a host restriction factor that inhibits the replication of various viruses. This study elucidated the mechanism by which MARCH8 restricts respiratory syncytial virus (RSV) replication through selective degradation of the viral small hydrophobic (SH) protein. We demonstrated that MARCH8 directly interacts with RSV-SH and catalyzes its ubiquitination at lysine 13, leading to SH degradation via the ubiquitin-lysosomal pathway. Functionally, MARCH8 expression enhances RSV-induced apoptosis through SH degradation, ultimately reducing viral titers. Conversely, an RSV strain harboring the SH-K13R mutation exhibited prolonged SH protein stability and attenuated apoptosis in infected cells, even in the presence of MARCH8. Targeted depletion of MARCH8 enhances cellular survival and potentially increases viral persistence. These findings demonstrate that MARCH8 promotes the early elimination of virus-infected cells by abrogating the anti-apoptotic function of SH, thereby reducing viral transmission. Our study provides novel insights into the interplay between host restriction factors and viral evasion strategies, potentially providing new therapeutic approaches for RSV infections.

Indexed as

ApoptosisProteolysisUbiquitinUbiquitinationUbiquitin-Protein LigasesVirus ReplicationA549 CellsCell LineHEK293 CellsHost-Pathogen InteractionsHumansRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsViral ProteinsMARCHF8 protein, humanUbiquitinUbiquitin-Protein LigasesViral ProteinsapoptosisMARCH8respiratory syncytial virussmall hydrophobic proteinubiquitination

Identifiers

PMID39772241
PMCPMC11680241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.